Market closed
Ironwood Pharmaceuticals/$IRWD
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Ironwood Pharmaceuticals
Ironwood Pharmaceuticals is a specialty and generic drug manufacturing company that operates a human therapeutics segment. The company is focused on advancing innovative product opportunities in areas of large unmet need, including irritable bowel syndrome with constipation, chronic idiopathic constipation, hyperuricemia associated with uncontrolled gout, uncontrolled gastroesophageal reflux disease, and vascular and fibrotic diseases. The company considers collaborative licenses, commercial agreements, and acquisition investment to be potential components of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.
Ticker
$IRWD
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
267
Website
IRWD Metrics
BasicAdvanced
$805M
Market cap
89.05
P/E ratio
$0.06
EPS
0.52
Beta
-
Dividend rate
Price and volume
Market cap
$805M
Beta
0.52
52-week high
$15.70
52-week low
$3.79
Average daily volume
1.3M
Financial strength
Current ratio
3.915
Quick ratio
3.596
Long term debt to equity
-198.025
Total debt to equity
-199.006
Interest coverage (TTM)
3.59%
Management effectiveness
Return on assets (TTM)
14.93%
Return on equity (TTM)
-2.15%
Valuation
Price to earnings (TTM)
89.046
Price to revenue (TTM)
1.977
Price to book
-2.5
Price to tangible book (TTM)
-2.48
Price to free cash flow (TTM)
5.412
Growth
Revenue change (TTM)
-6.25%
Earnings per share change (TTM)
-100.95%
3-year revenue growth (CAGR)
-1.02%
3-year earnings per share growth (CAGR)
-73.76%
What the Analysts think about IRWD
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Ironwood Pharmaceuticals stock.
IRWD Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
IRWD Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
IRWD News
AllArticlesVideos
Ironwood Pharmaceuticals, Inc. (IRWD) Q3 2024 Earnings Call Transcript
Seeking Alpha·10 hours ago
Once-Weekly Apraglutide Showed Consistent Treatment Effect Across Baseline Demographics and Disease Characteristics in Adults with Short Bowel Syndrome with Intestinal Failure (SBS-IF), According to New STARS Phase III Data from Ironwood at ACG 2024
Business Wire·2 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Ironwood Pharmaceuticals stock?
Ironwood Pharmaceuticals (IRWD) has a market cap of $805M as of November 08, 2024.
What is the P/E ratio for Ironwood Pharmaceuticals stock?
The price to earnings (P/E) ratio for Ironwood Pharmaceuticals (IRWD) stock is 89.05 as of November 08, 2024.
Does Ironwood Pharmaceuticals stock pay dividends?
No, Ironwood Pharmaceuticals (IRWD) stock does not pay dividends to its shareholders as of November 08, 2024.
When is the next Ironwood Pharmaceuticals dividend payment date?
Ironwood Pharmaceuticals (IRWD) stock does not pay dividends to its shareholders.
What is the beta indicator for Ironwood Pharmaceuticals?
Ironwood Pharmaceuticals (IRWD) has a beta rating of 0.52. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.